Welcome to LookChem.com Sign In|Join Free

CAS

  • or

3235-69-6

Post Buying Request

3235-69-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

3235-69-6 Usage

Uses

Morpholin-?4-?yl Acetic Acid was used in preparation of pyrrolidine-fused fullerene multicarboxylates by photoreaction.

Check Digit Verification of cas no

The CAS Registry Mumber 3235-69-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,2,3 and 5 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 3235-69:
(6*3)+(5*2)+(4*3)+(3*5)+(2*6)+(1*9)=76
76 % 10 = 6
So 3235-69-6 is a valid CAS Registry Number.
InChI:InChI=1/C6H11NO3/c8-6(9)5-7-1-3-10-4-2-7/h1-5H2,(H,8,9)

3235-69-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-morpholin-4-ylacetic acid

1.2 Other means of identification

Product number -
Other names 2-Morpholinoacetic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:3235-69-6 SDS

3235-69-6Synthetic route

(4-morpholinyl)acetic acid 1,1-dimethylethyl ester
88217-68-9

(4-morpholinyl)acetic acid 1,1-dimethylethyl ester

morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

Conditions
ConditionsYield
With potassium tert-butylate In tetrahydrofuran at 0℃; for 0.5h; Hydrolysis;100%
In water; isopropyl alcohol at 160℃; for 0.4h; Solvent; Temperature; Flow reactor;95%
With trifluoroacetic acid In dichloromethane at 20℃; for 5h;
benzyl morpholino-acetate
53342-23-7

benzyl morpholino-acetate

morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

Conditions
ConditionsYield
With hydrogen; palladium on activated charcoal In methanol for 40h;98%
With potassium tert-butylate In tetrahydrofuran at 0℃; for 5h; Hydrolysis;97%
N-morpholylacetic acid ethyl ester
3235-82-3

N-morpholylacetic acid ethyl ester

morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

Conditions
ConditionsYield
With hydrogenchloride In water at 95℃; for 16h; Temperature; Time;96.3%
With water for 30h; Hydrolysis; Heating;87%
With sodium hydroxide In water Heating;65%
methyl 2-morpholin-4-ylacetate
35855-10-8

methyl 2-morpholin-4-ylacetate

morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

Conditions
ConditionsYield
Stage #1: methyl 2-morpholin-4-ylacetate With methanol; sodium hydroxide; water In tetrahydrofuran at 50℃; for 1h;
Stage #2: With hydrogenchloride In tetrahydrofuran; water pH=3;
90%
With water; lithium hydroxide In methanol at 20℃; for 3h; Inert atmosphere;
morpholine
110-91-8

morpholine

bromoacetic acid
79-08-3

bromoacetic acid

morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 20℃; Inert atmosphere;85.3%
morpholine
110-91-8

morpholine

bromoacetic acid tert-butyl ester
5292-43-3

bromoacetic acid tert-butyl ester

morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

Conditions
ConditionsYield
In tetrahydrofuran; hydrogenchloride; ethyl acetate85%
In tetrahydrofuran; hydrogenchloride; ethyl acetate85%
morpholine
110-91-8

morpholine

4-(morpholinomethyl)morpholine
5625-90-1

4-(morpholinomethyl)morpholine

potassium cyanide
151-50-8

potassium cyanide

morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

Conditions
ConditionsYield
With water
morpholine
110-91-8

morpholine

sodium monochloroacetic acid
3926-62-3

sodium monochloroacetic acid

morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

Conditions
ConditionsYield
With water
5-(2-morpholinoacetamido)-3,3-di-p-tolyl-2-indolinone hydrochloride

5-(2-morpholinoacetamido)-3,3-di-p-tolyl-2-indolinone hydrochloride

A

morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

B

5-Amino-3,3-di-p-tolyl-1,3-dihydro-indol-2-one

5-Amino-3,3-di-p-tolyl-1,3-dihydro-indol-2-one

Conditions
ConditionsYield
With hydrogenchloride; water In acetic acid at 69.9 - 95.9℃; Rate constant; Kinetics; Thermodynamic data; ΔS(activ.), ΔH(activ.), ΔG(activ.);
morpholine
110-91-8

morpholine

chloroacetic acid ethyl ester
105-39-5

chloroacetic acid ethyl ester

morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

Conditions
ConditionsYield
With sodium hydroxide In 1,4-dioxane; benzene
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

(S)-benzyl 2-((S)-2-((tert-butoxycarbonyl)amino)-4-phenylbutanamido)-4-methylpentanoate hydrogen chloride salt

(S)-benzyl 2-((S)-2-((tert-butoxycarbonyl)amino)-4-phenylbutanamido)-4-methylpentanoate hydrogen chloride salt

(S)-benzyl 4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanoate
1385032-88-1

(S)-benzyl 4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanoate

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; HATU In dichloromethane at 20℃;98%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

(S)-2-amino-N4-(tert-butoxy)-N1-((S)-1-((naphthalen-1-ylmethyl)amino)-1-oxopropan-2-yl)succinamide

(S)-2-amino-N4-(tert-butoxy)-N1-((S)-1-((naphthalen-1-ylmethyl)amino)-1-oxopropan-2-yl)succinamide

(S)-N4-(tert-butoxy)-2-(2-morpholinoacetamido)-N1-((S)-1-((naphthalen-1-ylmethyl)amino)-1-oxopropan-2-yl)succinamide

(S)-N4-(tert-butoxy)-2-(2-morpholinoacetamido)-N1-((S)-1-((naphthalen-1-ylmethyl)amino)-1-oxopropan-2-yl)succinamide

Conditions
ConditionsYield
With 1-hydroxy-7-aza-benzotriazole; N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide98%
1-hydroxy-pyrrolidine-2,5-dione
6066-82-6

1-hydroxy-pyrrolidine-2,5-dione

morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

2,5-dioxopyrrolidin-1-yl 2-morpholinoacetate

2,5-dioxopyrrolidin-1-yl 2-morpholinoacetate

Conditions
ConditionsYield
With thionyl chloride In tetrahydrofuran; N,N-dimethyl-formamide at 20℃;96%
With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 1h;78%
With thionyl chloride; N,N-dimethyl-formamide In tetrahydrofuran at 0 - 20℃;67%
With thionyl chloride; N,N-dimethyl-formamide In tetrahydrofuran at 20℃;
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

(8S,9S,10R,13S,14S,17S)-17-((E)-1-(hydroxyimino)ethyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)one

(8S,9S,10R,13S,14S,17S)-17-((E)-1-(hydroxyimino)ethyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)one

(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-((E)-1-(2-morpholinoacetoxyimino)ethyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one
1364709-87-4

(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-((E)-1-(2-morpholinoacetoxyimino)ethyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In dichloromethane at 0 - 20℃; for 18h; Inert atmosphere;94%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

(8S,9S,10R,13S,14S,17S)-17-((E)-1-(hydroxyimino)ethyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one
1364709-15-8

(8S,9S,10R,13S,14S,17S)-17-((E)-1-(hydroxyimino)ethyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-((E)-1-(2-morpholinoacetoxyimino)ethyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one
1364709-87-4

(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-((E)-1-(2-morpholinoacetoxyimino)ethyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In dichloromethane at 0 - 20℃; for 18h; Inert atmosphere;94%
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In dichloromethane at 0 - 20℃; for 18h; Inert atmosphere;94%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

methyl 3-(4-chlorophenylamino)propanoate
21911-88-6

methyl 3-(4-chlorophenylamino)propanoate

C16H21ClN2O4

C16H21ClN2O4

Conditions
ConditionsYield
Stage #1: morpholin-4-ylacetic acid With thionyl chloride In dichloromethane at 10 - 20℃; for 2h;
Stage #2: methyl 3-(4-chlorophenylamino)propanoate With triethylamine In dichloromethane at 20℃; for 2.5h; Temperature;
92%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

C39H58O5

C39H58O5

C45H67NO7

C45H67NO7

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;92%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

(E)-4-(2-phenyl-1-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)but-1-en-1-yl)aniline

(E)-4-(2-phenyl-1-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)but-1-en-1-yl)aniline

(E)-2-morpholino-N-(4-(2-phenyl-1-(4-(2-(pyrrolidin-1-yl)-ethoxy)phenyl)but-1-en-1-yl)phenyl)acetamide

(E)-2-morpholino-N-(4-(2-phenyl-1-(4-(2-(pyrrolidin-1-yl)-ethoxy)phenyl)but-1-en-1-yl)phenyl)acetamide

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 4h; Inert atmosphere;91%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

1-adamantan-1-yl-2-(5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidin-4-ylamino)-ethanol

1-adamantan-1-yl-2-(5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidin-4-ylamino)-ethanol

1-[4-(2-adamantan-1-yl-2-hydroxy-ethylamino)-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl]-2-morpholin-4-yl-ethanone

1-[4-(2-adamantan-1-yl-2-hydroxy-ethylamino)-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl]-2-morpholin-4-yl-ethanone

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃;90%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

C20H29N5O6

C20H29N5O6

C21H30N6O6

C21H30N6O6

Conditions
ConditionsYield
Stage #1: C20H29N5O6 With trifluoroacetic acid
Stage #2: morpholin-4-ylacetic acid With HCTU; N-ethyl-N,N-diisopropylamine In dichloromethane
90%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

3-Iodoaniline
626-01-7

3-Iodoaniline

C12H15IN2O2

C12H15IN2O2

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide Inert atmosphere;89.9%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

(S)-N-((S)-2-amino-1-cyclohexylethyl)-3-(6-isopropylbenzo[d]thiazol-2-yl)-2-propionamidopropanamide

(S)-N-((S)-2-amino-1-cyclohexylethyl)-3-(6-isopropylbenzo[d]thiazol-2-yl)-2-propionamidopropanamide

(S)-N-((S)-1-cyclohexyl-2-(2-morpholinoacetamido)ethyl)-3-(6-isopropylbenzo[d]thiazol-2-yl)-2-propionamidopropanamide

(S)-N-((S)-1-cyclohexyl-2-(2-morpholinoacetamido)ethyl)-3-(6-isopropylbenzo[d]thiazol-2-yl)-2-propionamidopropanamide

Conditions
ConditionsYield
With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 1h;87%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

2-Morpholinoessigsaeure-N-oxid
87439-12-1

2-Morpholinoessigsaeure-N-oxid

Conditions
ConditionsYield
With dihydrogen peroxide In acetic acid at 60℃; for 12h;86%
Brivanib
649735-46-6

Brivanib

morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

C25H28FN5O5
1016195-07-5

C25H28FN5O5

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; dmap In N,N-dimethyl-formamide85%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

C31H34F26O5
1021458-90-1

C31H34F26O5

C37H43F26NO7
1021458-80-9

C37H43F26NO7

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 72h;84%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

C41H52F12O7
1021458-94-5

C41H52F12O7

C47H61F12NO9
1021458-71-8

C47H61F12NO9

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 24h;82%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

(E)-4-(1-(4-(2-morpholinoethoxy)phenyl)-2-phenylbut-1-en-1-yl)aniline

(E)-4-(1-(4-(2-morpholinoethoxy)phenyl)-2-phenylbut-1-en-1-yl)aniline

(E)-2-morpholino-N-(4-(1-(4-(2-morpholinoethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenyl)acetamide

(E)-2-morpholino-N-(4-(1-(4-(2-morpholinoethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenyl)acetamide

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 4h; Inert atmosphere;82%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

(S)-3-(3-(7-(3-aminopropoxy)-5-carbamoyl-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1H-benzo[d]imidazol-1-yl)propyl)-2-(1-ethyl-4-fluoro-3-methyl-1H-pyrazole-5-carboxamido)-3,4-dihydro-5-oxa-1,2a-diazaacenaphthylene-7-carboxamide hydrochloride

(S)-3-(3-(7-(3-aminopropoxy)-5-carbamoyl-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1H-benzo[d]imidazol-1-yl)propyl)-2-(1-ethyl-4-fluoro-3-methyl-1H-pyrazole-5-carboxamido)-3,4-dihydro-5-oxa-1,2a-diazaacenaphthylene-7-carboxamide hydrochloride

(S)-3-(3-(5-carbamoyl-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-(3-(2-morpholinoacetamido)propoxy)-1H-benzo[d]imidazol-1-yl)propyl)-2-(1-ethyl-4-fluoro-3-methyl-1H-pyrazole-5-carboxamido)-3,4-dihydro-5-oxa-1,2a-diazaacenaphthylene-7-carboxamide

(S)-3-(3-(5-carbamoyl-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-(3-(2-morpholinoacetamido)propoxy)-1H-benzo[d]imidazol-1-yl)propyl)-2-(1-ethyl-4-fluoro-3-methyl-1H-pyrazole-5-carboxamido)-3,4-dihydro-5-oxa-1,2a-diazaacenaphthylene-7-carboxamide

Conditions
ConditionsYield
With benzotriazol-1-ol; HATU In N,N-dimethyl-formamide at 20 - 27℃;81%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

N-(3S-amino-2R-hydroxy-4-phenylbutyl)-N-isobutyl-4-nitro-benzenesulfonamide hydrochloride
251105-80-3

N-(3S-amino-2R-hydroxy-4-phenylbutyl)-N-isobutyl-4-nitro-benzenesulfonamide hydrochloride

N-((2S,3R)-3-hydroxy-4-((N-isobutyl-4-nitrophenyl)sulfonamido)-1-phenylbutan-2-yl)-2-morpholinoacetamide

N-((2S,3R)-3-hydroxy-4-((N-isobutyl-4-nitrophenyl)sulfonamido)-1-phenylbutan-2-yl)-2-morpholinoacetamide

Conditions
ConditionsYield
Stage #1: morpholin-4-ylacetic acid; N-(3S-amino-2R-hydroxy-4-phenylbutyl)-N-isobutyl-4-nitro-benzenesulfonamide hydrochloride With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 0 - 25℃; Inert atmosphere; Sealed tube;
Stage #2: With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 25℃; Inert atmosphere; Sealed tube;
80%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

sofosbuvir
1190307-88-0

sofosbuvir

isopropyl ((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-4-methyl-3-(2-morpholinoacetoxy)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate

isopropyl ((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-4-methyl-3-(2-morpholinoacetoxy)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate

Conditions
ConditionsYield
Stage #1: morpholin-4-ylacetic acid; sofosbuvir With N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 0.0833333h;
Stage #2: With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate In dichloromethane for 20h;
76%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

C37H56O4

C37H56O4

C43H65NO6

C43H65NO6

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;75.9%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

C11H15N3O3

C11H15N3O3

C17H24N4O5

C17H24N4O5

Conditions
ConditionsYield
With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 24h; Enzymatic reaction;75%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

N-((2R,3S)-3-amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-4-methoxybenzenesulfonamide
159005-71-7

N-((2R,3S)-3-amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-4-methoxybenzenesulfonamide

N-((2S,3R)-3-hydroxy-4-((N-isobutyl-4-methoxyphenyl)sulfonamido)-1-phenylbutan-2-yl)-2-morpholinoacetamide

N-((2S,3R)-3-hydroxy-4-((N-isobutyl-4-methoxyphenyl)sulfonamido)-1-phenylbutan-2-yl)-2-morpholinoacetamide

Conditions
ConditionsYield
Stage #1: morpholin-4-ylacetic acid; N-((2R,3S)-3-amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-4-methoxybenzenesulfonamide With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 0 - 25℃; Inert atmosphere; Sealed tube;
Stage #2: With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 25℃; Inert atmosphere; Sealed tube;
75%
morpholin-4-ylacetic acid
3235-69-6

morpholin-4-ylacetic acid

C13H18N2O4*C2HF3O2

C13H18N2O4*C2HF3O2

(S)-methyl 3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanoate
1620107-79-0

(S)-methyl 3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanoate

Conditions
ConditionsYield
With benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In tetrahydrofuran for 1h;75%

3235-69-6Relevant articles and documents

Design, synthesis and biological evaluation of HIV-1 protease inhibitors with morpholine derivatives as P2 ligands in combination with cyclopropyl as P1′ ligand

Dong, Biao,Dou, Yue,Wang, Ju-Xian,Wang, Yu-Cheng,Zhang, Fan,Zhang, Guo-Ning,Zhu, Mei

, (2020)

A series of novel HIV-1 protease inhibitors has been designed and synthesized, which contained morpholine derivatives as the P2 ligands and hydrophobic cyclopropyl as the P1′ ligand at the meantime in this study, with the aim of improving the interactions between the active sites of HIV-1 protease and the inhibitors. Twenty-eight compounds were synthesized and assessed, among which inhibitors m18 and m1 exhibited excellent inhibitory effect on the activity of HIV-1 protease with IC50 value of 47 nM and 53 nM, respectively. The molecular modeling of m1 revealed possible hydrogen bondings or van der Waals between the inhibitor and the protease, worthy of in-depth study.

Nitrogen-containing cyclic compounds as iminium ion sources for selected reaction monitoring detection of derivatized analytes

?ilionis, Andrius

supporting information, p. 25 - 35 (2019/09/03)

Liquid chromatography–tandem mass spectrometry is one of the most sensitive tools for determination of trace amounts of analytes in metabolomics and proteomics. The highest sensitivity is achieved in selected reaction monitoring detection, which involves fragmentation of the molecular ion between two levels of mass selection. However, fragmentation of some compounds is complicated. Detection sensitivity of such analytes may be increased by derivatizing them with a specific moiety fragmentation of which results in product ion of high abundance. In this work, we reveal the influence of iminium ions' structures on their stability by comparing six nitrogen-containing cyclic compounds as derivatization reagents for tandem mass spectrometric analysis of amino group-containing analyte. Commercially available starting materials (piperidine, 2,6-dimethylpiperidine, 1-methylpiperazine, morpholine, pyrrolidine and 1-cyanomethyl-3-methylimidazolium ionic liquid) were used for the synthesis of corresponding carboxylic acids which were further used for derivatization of the model analyte tryptamine. Liquid chromatographic–mass spectrometric analysis of differently derivatized tryptamine was performed for the evaluation of release and stability of corresponding iminium ions under collision-induced dissociation conditions. As a result, morpholine moiety was shown being the most promising iminium ion source among tested compounds. Possible sub-fragmentation pathways of investigated iminium ions were discussed, and the structures of secondary product ions were proposed.

Development of a series of bis-triazoles as G-quadruplex ligands

Saleh, Maysaa M.,Laughton, Charles A.,Bradshaw, Tracey D.,Moody, Christopher J.

, p. 47297 - 47308 (2017/10/19)

Maintenance of telomeres-specialized complexes that protect the ends of chromosomes-is provided by the enzyme complex telomerase, which is a key factor that is activated in more than 80% of cancer cells, but absent in most normal cells. Targeting telomere maintenance mechanisms could potentially halt tumour growth across a broad spectrum of cancer types. Telomeric ends of chromosomes consist of noncoding repeat sequences of guanine-rich DNA. These G-rich ends can fold into structures called G-quadruplexes. Stabilization of G-quadruplexes by small binding molecules called G4 ligands can prevent telomerase enzyme from maintaining telomere integrity in cancer cells. G-quadruplexes can exist in other parts of the genome too, especially within promoter sequences of oncogenes, and also be interesting drug targets. Here, we describe the development of a new series of novel bis-triazoles, designed to stabilize G-quadruplex structures selectively as G4 ligands. FRET assays showed two compounds to be moderately effective G4 binders, with particular affinity for the quadruplex formed by the Hsp90a promoter sequence, and good selectivity for G-quadruplex DNA vs. duplex DNA. However, CD spectroscopy failed to provide any information about the folding topology of the human telomeric G-quadruplex resulting from its interaction with one of the ligands. All the new ligands showed potent cell growth inhibitory properties against human colon and pancreatic cancer cell lines, as evidenced by the MTT assay; notably, they were more potent against cancer cells than in fetal lung fibroblasts. Docking studies were performed to rationalize the affinity of these ligands for binding to the telomeric parallel G-quadruplex DNA.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 3235-69-6